Entering Scheme 9 Results
Results for scheme 9 are to be submitted via our bespoke participant’s portal. If you are unable to submit any results using the portal, please feel free to contact us to discuss alternative ways of submission.
Participant's Portal
Scheme 9 Results Entry Guidelines
Indicate the KIR genotype for each sample using the dropdown boxes, relevant to your assessment level.
Positive = KIR gene is present
Negative = KIR gene is absent
Technical issues/invalid results (e.g. control failures, quality issues) should be reported as ‘Not tested’. Reasons for not testing need to be reported on the final result entry page. ‘Not tested’ results will not be assessed.
Subtypes for 2DS4 and 3DP1 may be reported as FULL or DEL (optional, not assessed).
Other polymorphisms or subtype information may be reported in the comments box.
The KIR haplotype will not be formally assessed for the 2023-2024 distribution year. However, we do encourage participants to record these results in the comments box, e.g. Cen B/B and Tel A/A.
UK NEQAS for H&I acknowledge that the literature is varied in terms of KIR haplotype interpretation. However, we would encourage participants to use the above format and the following paper as a basis for its calculation of haplotype:
Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010 Oct 7;116(14):2411-9. doi: 10.1182/blood-2010-05-283051. Epub 2010 Jun 25. PMID: 20581313; PMCID: PMC2953880.
If you follow different guidance, please feel free to report the KIR haplotype, but please do also include the guidance document you are referring to.
For any queries with reporting contact ukneqashandi@wales.nhs.uk